There are 30 resources available
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
Presenter: Victor Moreno
Session: Proffered Papers 2: Individual targets
Resources:
Abstract
CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
Presenter: Antoine Hollebecque
Session: Proffered Papers 2: Individual targets
Resources:
Abstract
A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC)
Presenter: Philippe Bedard
Session: Proffered Papers 2: Individual targets
Resources:
Abstract
A first-in-human phase I study of MORAb-202 in patients with folate receptor alpha-positive advanced solid tumors
Presenter: Jun Sato
Session: Proffered Papers 2: Individual targets
Resources:
Abstract
Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Eric Angevin
Session: Poster Display & Cocktail
Resources:
Abstract
Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
Presenter: Guillermo Prado
Session: Poster Display & Cocktail
Resources:
Abstract
A mitigation of breast cancer-induced immune-suppressive tumor microenvironment through curbing miR-155/IL-10/TNF-α loop using a novel quercetin derivative
Presenter: Rana Youness
Session: Poster Display & Cocktail
Resources:
Abstract
Association between baseline tumor size and outcome in patients treated with next-generation immunoncology agents
Presenter: Paolo Tarantino
Session: Poster Display & Cocktail
Resources:
Abstract
IL-18 improves the anti-cancer immunity of human gamma delta T cells against prostate cancer
Presenter: Mohanad Nada
Session: Poster Display & Cocktail
Resources:
Abstract
In vitro and in vivo cytolethal and antitumor effects of a novel fusion protein targeting IL-24 toward breast cancer cells
Presenter: Ali Jahanian-Najafabadi
Session: Poster Display & Cocktail
Resources:
Abstract